4:11 PM ET
8-K
Executive Compensation
Crispr Therapeutics Executive Compensation
CRISPR Therapeutics promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Under his new employment agreement, Mr. Silver will receive an annual base salary of $515,000, a target bonus of 45%, and a one-time grant of 25,000 restricted stock units vesting over two years.